359 related articles for article (PubMed ID: 20181711)
1. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
2. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.
Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD
Antimicrob Agents Chemother; 1998 Nov; 42(11):2923-31. PubMed ID: 9797227
[TBL] [Abstract][Full Text] [Related]
3. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.
Moore SM; Cannon JS; Tanhehco YC; Hamzeh FM; Ambinder RF
Antimicrob Agents Chemother; 2001 Jul; 45(7):2082-91. PubMed ID: 11408227
[TBL] [Abstract][Full Text] [Related]
4. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
Koyano S; Suzutani T; Yoshida I; Azuma M
Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a thymidine kinase-deficient mutant of equine herpesvirus 4 and in vitro susceptibility of the virus to antiviral agents.
Azab W; Tsujimura K; Kato K; Arii J; Morimoto T; Kawaguchi Y; Tohya Y; Matsumura T; Akashi H
Antiviral Res; 2010 Feb; 85(2):389-95. PubMed ID: 19931566
[TBL] [Abstract][Full Text] [Related]
6. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.
Lin JC; Smith MC; Pagano JS
J Virol; 1984 Apr; 50(1):50-5. PubMed ID: 6321799
[TBL] [Abstract][Full Text] [Related]
7. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T; Lixin W; Takayama-Ito M; Iizuka I; Ogata M; Tsuji M; Nishimura H; Taniguchi S; Morikawa S; Kurane I; Mizuguchi M; Saijo M
Antiviral Res; 2011 Aug; 91(2):142-9. PubMed ID: 21669227
[TBL] [Abstract][Full Text] [Related]
8. Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1.
Schalkwijk HH; Shewakramani NR; Das K; Andrei G; Snoeck R
Antimicrob Agents Chemother; 2024 May; 68(5):e0011024. PubMed ID: 38619252
[TBL] [Abstract][Full Text] [Related]
9. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1.
Bae PK; Kim JH; Kim HS; Chung IK; Paik SG; Lee CK
Antiviral Res; 2006 Jul; 70(3):93-104. PubMed ID: 16546268
[TBL] [Abstract][Full Text] [Related]
10. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir.
Keever-Taylor CA; Behn B; Konings S; Orentas R; Davies B; Margolis D
Cytotherapy; 2003; 5(4):323-35. PubMed ID: 12944239
[TBL] [Abstract][Full Text] [Related]
11. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.
Likar Y; Dobrenkov K; Olszewska M; Vider E; Shenker L; Cai S; Pillarsetty N; Hricak H; Ponomarev V
J Nucl Med; 2008 May; 49(5):713-20. PubMed ID: 18413388
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinase.
Hussein IT; Miguel RN; Tiley LS; Field HJ
Arch Virol; 2008; 153(3):495-505. PubMed ID: 18196203
[TBL] [Abstract][Full Text] [Related]
13. A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.
McSorley T; Ort S; Monnerjahn C; Konrad M
Biochem Pharmacol; 2014 Feb; 87(3):435-44. PubMed ID: 24316433
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
[TBL] [Abstract][Full Text] [Related]
15. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Wildner O; Hoffmann D; Jogler C; Uberla K
Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232
[TBL] [Abstract][Full Text] [Related]
17. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system.
Hayashi K; Hayashi T; Sun HD; Takeda Y
Hum Gene Ther; 2002 Feb; 13(3):415-23. PubMed ID: 11860708
[TBL] [Abstract][Full Text] [Related]
18. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.
Balzarini J; Liekens S; Esnouf R; De Clercq E
Biochemistry; 2002 May; 41(20):6517-24. PubMed ID: 12009916
[TBL] [Abstract][Full Text] [Related]
19. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
20. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
